Clinical Trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2020-06-14; most recent amendment 2026-04-28.
Status change: Active, Not Recruiting → Recruiting 2025-08-14
Status change: Recruiting → Active, Not Recruiting 2023-06-19
Status change: Suspended → Recruiting 2021-10-20
Status change: Recruiting → Suspended 2020-10-19
Status change: Not Yet Recruiting → Recruiting 2020-07-07
Trial Details
NCT Number NCT04434040
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Genentech, Inc., Stand Up To Cancer
Conditions Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
Enrollment 40 participants
Start Date 2020-07-02
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-04